Insights from GSK's Chief Scientist on the Role of Technology in R&D

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going to be massively compressed," Dr. Tony Wood, Chief Scientific Officer at GSK, explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Dr. Wood joins BI analyst Sam Fazeli to address the disconnect between market expectations for its future drugs in the context of GSK's R&D strategy and technology leverage. The company has five potential new drug approvals in 2025 and sees its early stage investments in AI and ML holding huge potential to catalyze future drug discovery and development.See omnystudio.com/listener for privacy information.